Plan de negocios del proyecto inmobiliario "Valle Real"

The real estate business plan for the "Valle Real" Project, seeks to analyze and demonstrate the feasibility of the project. Through the inclusion of macroeconomic analysis, economic, financial, legal and marketing factors you can develop a strategy to get the best opportunities. The project runs on a land area of 2001.37 m2, with 1 underground parking, and 21 homes of 2 and 3 floors with green areas. In determining the macroeconomic variables a market study is done to determine the customer profile, and characteristics that must exist in the project, and to determine if this project is properly focused on the potential customer is looking for. It is involved in cost analysis and a financial analysis is obtained, taking into account the budget, the expenses incurred on the project and the discount rate adopted by the promoter, to determine whether the Valle Real project is financially viable, fulfilling the requirements environmental laws.El plan de negocio inmobiliario para el Proyecto “Valle Real”, busca analizar y demostrar la viabilidad del proyecto. Por medio de la inclusión de un análisis de factores macroeconómicos, económicos, financieros, legales y de marketing se podrá desarrollar una estrategia que permita obtener las mejores oportunidades. El proyecto se ejecuta en un área de terreno de 2001.37 m2, cuenta con 1 subsuelo de parqueaderos, y 21 viviendas de 2 y 3 pisos con áreas verdes. Al determinar las variables macroeconómicas se realiza un estudio de mercado para determinar el perfil del cliente, y las características que deben existir en el proyecto, y poder determinar si este proyecto se encuentra correctamente enfocado al potencial cliente que se busca. Se interviene en el análisis de costos y se obtiene un análisis financiero, tomando en cuenta el presupuesto, los gastos generados en el proyecto y la tasa de descuento adoptada por el promotor, para determinar si el proyecto Valle Real es viable financieramente, cumpliendo las exigencias legales del medio

Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry

Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients >= 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were >= 80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29-0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22-0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19

Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain

Older age and cardiovascular comorbidities are well-known risk factors for all-cause mortality in patients with coronavirus disease 2019 (COVID-19). Hypertension and age are the 2 principal determinants of arterial stiffness (AS). This study aimed to estimate AS in patients with COVID-19 requiring hospitalization and analyze its association with all-cause in-hospital mortality. This observational, retrospective, multicenter cohort study analyzed 12 170 patients admitted to 150 Spanish centers included in the SEMI-COVID-19 Network. We compared AS, defined as pulse pressure ≥60 mm Hg, and clinical characteristics between survivors and nonsurvivors. Mean age was 67.5 (±16.1) years and 42.5% were women. Overall, 2606 (21.4%) subjects died. Admission systolic blood pressure (BP) <120 and ≥140 mm Hg was a predictor of higher all-cause mortality (23.5% and 22.8%, respectively, P<0.001), compared with systolic BP between 120 and 140 mm Hg (18.6%). The 4379 patients with AS (36.0%) were older and had higher systolic and lower diastolic BP. Multivariate analysis showed that AS and systolic BP <120 mm Hg significantly and independently predicted all-cause in-hospital mortality (adjusted odds ratio [ORadj]: 1.27, P=0.0001; ORadj: 1.48, P=0.0001, respectively) after adjusting for sex (males, ORadj: 1.6, P=0.0001), age tertiles (second and third tertiles, ORadj: 2.0 and 4.7, P=0.0001), Charlson Comorbidity Index (second and third tertiles, ORadj: 4.8 and 8.6, P=0.0001), heart failure, and previous and in-hospital antihypertensive treatment. Our data show that AS and admission systolic BP <120 mm Hg had independent prognostic value for all-cause mortality in patients with COVID-19 requiring hospitalization